ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding ProPhase Labs, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 27 | 32 | +5 |
| Shares | 1.69M | 1.70M | +11.4K (+0.7%) |
| Value | $7.63M | $11.0M | +$3.34M (+43.8%) |
New holders (6)
Institutions that held ProPhase Labs, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 54,648 | $353.6K | 0.00% |
| Citadel Advisors LLC | 6,773 | $43.8K | 0.00% |
| UBS Group AG | 3,323 | $21.5K | 0.00% |
| CoreCap Advisors, LLC | 100 | $647 | 0.00% |
| Spire Wealth Management | 80 | $518 | 0.00% |
| Jamison Private Wealth Management, Inc. | 3,000 | $0 | 0.00% |
Sold out (1)
Institutions that held ProPhase Labs, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Advisory Services Network, LLC | 600 | $2.71K |